NO20053965L - Fremgangsmate for fremstilling av belagt preparat - Google Patents
Fremgangsmate for fremstilling av belagt preparatInfo
- Publication number
- NO20053965L NO20053965L NO20053965A NO20053965A NO20053965L NO 20053965 L NO20053965 L NO 20053965L NO 20053965 A NO20053965 A NO 20053965A NO 20053965 A NO20053965 A NO 20053965A NO 20053965 L NO20053965 L NO 20053965L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- coated
- pioglitazone hydrochloride
- remedy
- useful
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 abstract 2
- 229960002827 pioglitazone hydrochloride Drugs 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000010828 elution Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003020925 | 2003-01-29 | ||
| JP2003276894 | 2003-07-18 | ||
| JP2004001128 | 2004-01-06 | ||
| PCT/JP2004/000754 WO2004067001A1 (ja) | 2003-01-29 | 2004-01-28 | 被覆製剤の製造法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20053965L true NO20053965L (no) | 2005-08-25 |
Family
ID=32830627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053965A NO20053965L (no) | 2003-01-29 | 2005-08-25 | Fremgangsmate for fremstilling av belagt preparat |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7976853B2 (pl) |
| EP (1) | EP1588708A4 (pl) |
| KR (1) | KR101114808B1 (pl) |
| AU (1) | AU2004208606B2 (pl) |
| BR (1) | BRPI0407074A (pl) |
| CA (1) | CA2514539C (pl) |
| CR (1) | CR7929A (pl) |
| IL (1) | IL169870A (pl) |
| MA (1) | MA27624A1 (pl) |
| MX (1) | MXPA05007883A (pl) |
| NO (1) | NO20053965L (pl) |
| NZ (1) | NZ541749A (pl) |
| PL (1) | PL377403A1 (pl) |
| WO (1) | WO2004067001A1 (pl) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| KR100952090B1 (ko) | 2003-10-31 | 2010-04-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 인슐린 감작제, 인슐린 분비촉진제 및 폴리옥시에틸렌소르비탄 지방산 에스테르를 함유하는 고체 제제 |
| WO2005099760A1 (ja) | 2004-04-14 | 2005-10-27 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| GB0423964D0 (en) * | 2004-10-28 | 2004-12-01 | Jagotec Ag | Dosage form |
| TWI274889B (en) * | 2005-10-06 | 2007-03-01 | Elan Microelectronics Corp | Resistive touch screen measurement system |
| TWI384985B (zh) * | 2005-12-22 | 2013-02-11 | Takeda Pharmaceutical | 固體製劑 |
| WO2008018569A1 (en) * | 2006-08-10 | 2008-02-14 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
| DK2107905T3 (da) * | 2007-02-01 | 2011-01-31 | Takeda Pharmaceutical | Fast sammensætning omfattende alogliptin og pioglitazon |
| US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
| US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| MX2010001335A (es) | 2007-07-31 | 2010-06-02 | Lifescan Inc | Diferenciacion de celulas madre embrionarias humanas. |
| CN107574142B (zh) | 2007-11-27 | 2021-07-06 | 生命扫描有限公司 | 人胚胎干细胞的分化 |
| CN102046779A (zh) | 2008-02-21 | 2011-05-04 | 森托科尔奥索生物科技公司 | 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物 |
| US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| WO2009120844A2 (en) * | 2008-03-26 | 2009-10-01 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue |
| RU2533805C2 (ru) | 2008-06-30 | 2014-11-20 | Сентокор Орто Байотек Инк. | Дифференцирование плюрипотентных стволовых клеток, представляющих собой линию клеток человека |
| WO2010051223A1 (en) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
| AU2009316583B2 (en) | 2008-11-20 | 2016-04-21 | Janssen Biotech, Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
| CA2744234C (en) | 2008-11-20 | 2018-11-06 | Centocor Ortho Biotech Inc. | Pluripotent stem cell culture on micro-carriers |
| EP2456862A4 (en) | 2009-07-20 | 2013-02-27 | Janssen Biotech Inc | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS |
| RU2701335C2 (ru) | 2009-12-23 | 2019-09-25 | Янссен Байотек, Инк. | Способ получения популяции панкреатических эндокринных клеток, соэкспрессирующих nkx6.1 и инсулин, и способ лечения диабета |
| CN102791851B (zh) | 2010-03-01 | 2017-07-14 | 詹森生物科技公司 | 纯化衍生自多能干细胞的细胞的方法 |
| SG185511A1 (en) | 2010-05-12 | 2012-12-28 | Centocor Ortho Biotech Inc | Differentiation of human embryonic stem cells |
| EP2853589B1 (en) | 2010-08-31 | 2017-12-27 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| PH12013500367A1 (en) | 2010-08-31 | 2013-04-01 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
| JP2013538807A (ja) | 2010-09-01 | 2013-10-17 | ルピン・リミテッド | メトホルミンおよびピオグリタゾンを含む医薬組成物 |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| EP2794857B1 (en) | 2011-12-22 | 2026-02-11 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
| RU2664467C2 (ru) | 2012-03-07 | 2018-08-17 | Янссен Байотек, Инк. | Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток |
| KR102468315B1 (ko) | 2012-06-08 | 2022-11-16 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화 |
| EP2674149B1 (en) * | 2012-06-15 | 2017-10-04 | Shin-Etsu Chemical Co., Ltd. | Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation |
| AU2013370228B2 (en) | 2012-12-31 | 2018-10-18 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| DK2938724T3 (da) | 2012-12-31 | 2020-12-14 | Janssen Biotech Inc | Dyrkning af humane embryonale stamceller ved luft-væskegrænsefladen til differentiering til endokrine pankreasceller |
| BR112015015701A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | diferenciação de células-tronco embrionárias humanas em células pancreáticas endócrinas com o uso de reguladores hb9 |
| PT3011973T (pt) * | 2013-06-17 | 2019-03-25 | Nippon Soda Co | Agente de revestimento contendo hidroxialquicelulose |
| KR101597004B1 (ko) * | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
| SG11201609473XA (en) | 2014-05-16 | 2016-12-29 | Janssen Biotech Inc | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
| EP4450076A2 (en) | 2016-04-14 | 2024-10-23 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells to intestinal midgut endoderm cells |
| RU2690677C1 (ru) * | 2018-06-27 | 2019-06-05 | Георгий Георгиевич Чумбуридзе | Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью |
| CN112461947B (zh) * | 2020-10-27 | 2022-06-28 | 山东省药学科学院 | 一种盐酸吡格列酮片溶出曲线的测定方法 |
| CN120392688B (zh) * | 2025-07-02 | 2025-09-16 | 浙江大学 | 一种盐酸吡格列酮和二甲双胍复方片剂及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5179716A (en) | 1974-12-28 | 1976-07-12 | Shinetsu Chemical Co | Kokeiiyakuseizaino seizohoho |
| DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
| EP0616841B1 (en) * | 1992-10-09 | 1998-12-23 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Production method for fine granulate |
| US5651983A (en) | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
| CA2171827C (en) | 1993-09-15 | 2004-06-29 | Sankyo Company, Limited | Use of thiazolidinediones to prevent or delay onset of niddm |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| US6291495B1 (en) | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| SE9702000D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
| US20020004515A1 (en) | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
| KR20060105005A (ko) | 1997-06-18 | 2006-10-09 | 스미스클라인비이참피이엘시이 | 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료 |
| EA003101B1 (ru) | 1998-03-19 | 2002-12-26 | Бристол-Майерз Сквибб Компани | Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы |
| AU5652199A (en) | 1998-09-18 | 2000-04-10 | Takeda Chemical Industries Ltd. | Sustained release oral preparations |
| CA2347104A1 (en) | 1998-10-26 | 2000-04-05 | Tanabe Seiyaku Co., Ltd. | Sustained-release particles |
| OA11677A (en) | 1998-11-12 | 2005-01-12 | Smithkline Beecham Plc | Pharmaceutical composition for modified release ofan insulin sensitiser and another antidiabetic agent. |
| AR023699A1 (es) | 1998-11-12 | 2002-09-04 | Smithkline Beecham Corp | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6168806B1 (en) * | 1999-03-05 | 2001-01-02 | Fang-Yu Lee | Orally administrable nifedipine pellet and process for the preparation thereof |
| AU1403501A (en) * | 1999-11-16 | 2001-05-30 | Smithkline Beecham Plc | Novel composition and use |
| MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
| CA2399463A1 (en) * | 2000-02-10 | 2001-08-16 | Takeda Chemical Industries, Ltd. | Combination drug |
| US6610272B1 (en) | 2000-05-01 | 2003-08-26 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US6780432B1 (en) | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
| US6403121B1 (en) * | 2000-05-01 | 2002-06-11 | Aeropharm Technology Incorporated | Core formulation |
| US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
| JP2001342185A (ja) * | 2000-06-02 | 2001-12-11 | Nichiko Pharmaceutical Co Ltd | フィルムコーティングされた塩酸ラニチジン錠剤 |
| EP1738751B1 (en) | 2001-01-12 | 2011-05-11 | Sun Pharma Advanced Research Company Ltd | Spaced drug delivery system |
| JPWO2002060448A1 (ja) * | 2001-01-30 | 2004-05-27 | 帝人株式会社 | 医薬組成物 |
| JP2004536843A (ja) | 2001-07-10 | 2004-12-09 | エアロファーム テクノロジー インコーポレイテッド | ピオグリタゾンおよびビグアナイドを含むコア製剤 |
| US20030187074A1 (en) | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
| EP1515701B1 (en) | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide |
| AU2003281181A1 (en) | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
| US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| JP4694841B2 (ja) | 2002-09-20 | 2011-06-08 | アンドルックス ラボズ リミテッド ライアビリティ カンパニー | ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
| IN192749B (pl) * | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| WO2004069229A1 (en) | 2003-02-05 | 2004-08-19 | Ipca Laboratories Limited | Dual release anti-diabetic drugs and process of production thereof |
-
2004
- 2004-01-28 KR KR1020057013940A patent/KR101114808B1/ko not_active Expired - Fee Related
- 2004-01-28 US US10/542,997 patent/US7976853B2/en active Active
- 2004-01-28 PL PL377403A patent/PL377403A1/pl not_active Application Discontinuation
- 2004-01-28 WO PCT/JP2004/000754 patent/WO2004067001A1/ja not_active Ceased
- 2004-01-28 CA CA2514539A patent/CA2514539C/en not_active Expired - Fee Related
- 2004-01-28 AU AU2004208606A patent/AU2004208606B2/en not_active Ceased
- 2004-01-28 EP EP04705948A patent/EP1588708A4/en not_active Withdrawn
- 2004-01-28 MX MXPA05007883A patent/MXPA05007883A/es active IP Right Grant
- 2004-01-28 BR BR0407074-7A patent/BRPI0407074A/pt not_active Application Discontinuation
- 2004-01-28 NZ NZ541749A patent/NZ541749A/en not_active IP Right Cessation
-
2005
- 2005-07-25 IL IL169870A patent/IL169870A/en not_active IP Right Cessation
- 2005-08-01 CR CR7929A patent/CR7929A/es unknown
- 2005-08-24 MA MA28453A patent/MA27624A1/fr unknown
- 2005-08-25 NO NO20053965A patent/NO20053965L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA27624A1 (fr) | 2005-11-01 |
| PL377403A1 (pl) | 2006-02-06 |
| EP1588708A4 (en) | 2006-03-01 |
| EP1588708A1 (en) | 2005-10-26 |
| US20060141128A1 (en) | 2006-06-29 |
| CA2514539C (en) | 2012-03-06 |
| BRPI0407074A (pt) | 2006-01-24 |
| AU2004208606B2 (en) | 2009-09-24 |
| KR101114808B1 (ko) | 2012-02-15 |
| CR7929A (es) | 2005-11-28 |
| CA2514539A1 (en) | 2004-08-12 |
| MXPA05007883A (es) | 2005-09-21 |
| KR20050096958A (ko) | 2005-10-06 |
| AU2004208606A1 (en) | 2004-08-12 |
| NZ541749A (en) | 2009-06-26 |
| WO2004067001A1 (ja) | 2004-08-12 |
| IL169870A (en) | 2012-07-31 |
| US7976853B2 (en) | 2011-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053965L (no) | Fremgangsmate for fremstilling av belagt preparat | |
| AU2022402959A1 (en) | Dual-targeting compound, and preparation method therefor and use thereof | |
| NO20084912L (no) | Bisykliske derivater som CETP-inhibitorer | |
| EP4015520A4 (en) | OXYGEN-CONTAINING HETEROCYCLIC COMPOUND, PROCESS FOR THEIR PRODUCTION AND ITS USE | |
| ATE485849T1 (de) | Polymerzusammensetzungen, überzüge und vorrichtungen und herstellungs- und anwendungsverfahren damit | |
| CY2014042I2 (el) | Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζολιου, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδος για την παραγωγη τους | |
| NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
| NO20082278L (no) | Triazolderivater som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase-1 | |
| NO20070176L (no) | Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| MX2010004319A (es) | Compuesto de alfa-(n-sulfonamido)acetamida novedoso como un inhibidor de producccion de peptido beta amiloide. | |
| EP1638947A4 (en) | TRIAZONE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | |
| BRPI0717822A2 (pt) | Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto. | |
| NO20092634L (no) | Fremgangsmate for fremstilling av piperazinyl og diazepanyl benzamidderivater | |
| WO2021133016A3 (ko) | 헤테로고리 화합물, 이를 포함하는 유기 발광 소자, 유기 발광 소자의 유기물층용 조성물 및 유기 발광 소자의 제조 방법 | |
| EP2702988A3 (en) | Novel compositions and methods for treating hyperproliferative diseases | |
| NO20082112L (no) | 3-Amino-2-arylpropylazaindoler og deres anvendelse | |
| EP4186905A4 (en) | COMPOUND AS BTK INHIBITOR, METHOD OF PREPARING IT AND USE THEREOF | |
| EP3991857A4 (en) | Primary anticorrosion coating composition, substrate with primary anticorrosion coating membrane, and manufacturing method therefor | |
| NO20070565L (no) | Kinolin tiazolinoner med CDK1 antiproliferativ aktivitet | |
| NO20070564L (no) | Kinoliner uten tiazolinonsubstituenter. | |
| NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes | |
| EP4230563A4 (en) | CLAMPING MECHANISM AND METHODS OF USING THE CLAMPING MECHANISM | |
| BRPI0704496A (pt) | pigmentos de óxido férrico estáveis à oxidação, processo para a fabricação de pigmentos de óxido férrico, uso dos pigmentos de óxido férrico | |
| AU2007310767A1 (en) | New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |